EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Subinguinal Orchidectomy for Testicular Cancer: Innovation or Unnecessary Advancement

Dayan Jacob, Pragnitha Chitteti, Mohamed Mubarak, Mehwash Nadeem

Cureus · 15.06.2025

DOI: 10.7759/cureus.86062 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cureus, erschienen am 15.06.2025. Verfasst von Dayan Jacob und 3 weiteren Autor:innen. Beteiligte Einrichtung: Urology, James Cook University Hospital, Middlesbrough, GBR. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subinguinal orchidectomy is a variation of the traditional high inguinal approach for testicular cancer, differing in the level of spermatic cord excision. While the subinguinal approach preserves the inguinal canal and ilioinguinal nerve, concerns remain about the residual disease in the proximal cord and its impact on oncological outcomes. This review evaluates oncological outcomes and complications of subinguinal orchidectomy. A search was conducted across five databases (PubMed, Scopus, Google Scholar, Cochrane Library, and Embase). Studies reporting inguinal versus subinguinal orchidectomies, tumor grade, oncological outcomes, complications, and follow-up were included. Descriptive statistics were performed using Microsoft Excel (Microsoft Corporation, Redmond, WA). Of the 25 studies screened, two were eligible for review, including data from 264 patients (2000-2024). Subinguinal orchidectomy was done in 54.7% (n=144) of cases. Unsatisfactory oncological control was observed in 12.5% (n=18) of subinguinal cases, with 78% (n=14) due to cancer relapse, 16.5% (n=3) due to spermatic cord invasion (SCI), and 5.5% (n=1) due to positive margins. One study comparing subinguinal and high inguinal approaches found no differences in oncological outcomes for stage 1 and stage 2-4 cancers (p=0.91 and p=0.78, respectively). One study reported that 9.5% of patients who underwent subinguinal orchidectomy (n=4) developed seromas postoperatively. Current evidence, though limited, suggests no significant differences in oncological outcomes between subinguinal and high-inguinal orchidectomies. While retrospective studies support this, prospective trials are required to better evaluate the oncological risk-benefit ratio of subinguinal orchidectomy.

Schlagwörter

Stichwörter der Autor:innen

high orchidectomyorchidectomytesticular neoplasmsurology oncologyurology surgery

Autor:innen und Institutionen

  • Urology, James Cook University Hospital, Middlesbrough, GBR.

Zitieren

APA

Jacob, D., Chitteti, P., Mubarak, M., & Nadeem, M. (2025). Subinguinal Orchidectomy for Testicular Cancer: Innovation or Unnecessary Advancement. Cureus. https://doi.org/10.7759/cureus.86062

Vancouver

Jacob D, Chitteti P, Mubarak M, Nadeem M. Subinguinal Orchidectomy for Testicular Cancer: Innovation or Unnecessary Advancement. Cureus. 2025. doi:10.7759/cureus.86062

BibTeX
@article{Jacob2025,
  author = {Jacob, Dayan and Chitteti, Pragnitha and Mubarak, Mohamed and Nadeem, Mehwash},
  title = {Subinguinal Orchidectomy for Testicular Cancer: Innovation or Unnecessary Advancement},
  journal = {Cureus},
  year = {2025},
  doi = {10.7759/cureus.86062}
}
Kostenlos starten →